The weight-loss drug Wegovy slashes the risk of heart disease even before people shed many pounds, data suggests.The drug, which contains the active ingredient semaglutide, works by reducing food cravings and is also available for people with a high BMI.

The analysis of 11 weight-loss drug studies by the University of Oxford found that patients typically lost 8kg (18lb) after taking the jabs. However, participants returned to their original weight within 10 months of stopping the medication.

People who take Wegovy appear to be at greater risk for hair loss, according to an early study that hasn't yet been peer-reviewed. Females in the study were twice as likely to lose hair as males.

The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its push to lower prescription drug prices. President Donald Trump's executive order demands that drugmakers cut prices on their products in the coming months to hew more closely to what they charge in other developed countries,